세계의 근육 소모성 질환 시장 보고서(2025년)

Muscle wasting disorders, also known as muscle atrophy or muscle wasting, encompass a range of conditions marked by the gradual reduction of muscle mass and strength. This phenomenon can be attributed to various factors, such as lack of use, aging, malnutrition, neurodegenerative diseases, and specific medical conditions.

Primary treatments for muscle wasting disorders include medications, physical therapy, nutritional therapy, surgery, gene therapy, and various other interventions. Medications for muscle wasting disorders are specifically designed to address conditions such as sarcopenia, cachexia, and muscular dystrophy. The goal of these medications is to enhance muscle mass and improve overall muscle function. They find application in the treatment of conditions such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), and others, being utilized by hospitals, rehabilitation centers, specialty clinics, and other end-users.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The muscle wasting disorders market research report is one of a series of new reports from The Business Research Company that provides muscle wasting disorders market statistics, including muscle wasting disorders industry global market size, regional shares, competitors with a muscle wasting disorders market share, detailed muscle wasting disorders market segments, market trends and opportunities, and any further data you may need to thrive in the muscle wasting disorders industry. This muscle wasting disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The muscle wasting disorders market size has grown rapidly in recent years. It will grow from $15.06 billion in 2024 to $17.49 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increasing aging population, rising incidence of chronic diseases, advancements in research and development, increased awareness of early diagnosis, emerging therapeutic approaches.

The muscle wasting disorders market size is expected to see rapid growth in the next few years. It will grow to $29.52 billion in 2029 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to regulatory support, patient advocacy initiatives, healthcare infrastructure development, globalization of clinical trials, personalized medicine approaches. Major trends in the forecast period include telemedicine adoption, technological advancements in diagnostics, product innovation, collaborations and partnerships, advancements in therapeutics, research on molecular mechanisms, biopharmaceutical innovation.

The forecast of 14.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neuromuscular clinics by driving up the cost of myostatin inhibitors and electrical stimulation devices sourced from Switzerland and Japan, exacerbating functional decline in patients and raising rare disease care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in adherence to a sedentary lifestyle is poised to drive the growth of the muscle wasting disorders market in the future. A sedentary lifestyle, characterized by limited physical activity and minimal exercise, has been linked to negative impacts on muscle function. This can result in a reduction in muscle strength and endurance, contributing to muscle wasting disorders. In 2022, the World Health Organization reported that over 80% of adolescents and 27% of adults did not meet recommended physical activity levels. This trend towards a sedentary lifestyle is a significant factor propelling the expansion of the muscle wasting disorders market.

Key players in the muscle wasting disorders market are actively developing innovative products, particularly novel gene therapies, to better address the needs of patients with muscle wasting disorders. Novel gene therapy involves manipulating gene expression or altering the biological properties of living cells to achieve therapeutic effects. For example, Sarepta Therapeutics, a US-based biotechnology company, introduced Elevidys in June 2023. Elevidys, the first gene therapy approved by the U.S. FDA for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 to 5, utilizes recombinant gene therapy to deliver a gene leading to a shortened protein with selected domains of the dystrophin protein. The therapy is administered as a single intravenous infusion.

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals Inc. for $7.3 billion. This acquisition is expected to enhance Biogen's rare disease portfolio, specifically addressing Friedreich's ataxia - a genetic, progressive, and debilitating neuromuscular disorder affecting the nervous system and muscles. Reata Pharmaceuticals Inc., the acquired US-based pharmaceutical company, focuses on developing therapeutics for neuromuscular disorders and muscle wasting disorders, further solidifying Biogen's position in the market.

Major companies operating in the muscle wasting disorders market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Roche Holding AG, Novartis AG, Sanofi, GlaxoSmithKline (GSK), Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Acceleron Pharma Inc., Biogen Inc., Santhera Pharmaceuticals Holding AG, Mitsubishi Tanabe Pharma, Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.), Sarepta Therapeutics Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Axogen, Inc., FibroGen Inc., Cytokinetics Incorporated, Italfarmaco S.p.A., Scholar Rock, Bellerophon Therapeutics, Akashi Therapeutics, aTyr Pharma, Metabolic Solutions Development Company, Synaptogenix, MyoKardia, Inc., MyoTherix Inc.

North America was the largest region in the muscle wasting disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle wasting disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle wasting disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The muscle wasting disorders market consists of revenues earned by entities by providing services such as diagnostic services, medical services, support services and community services. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle wasting disorders market also includes sales of anabolic steroids, growth hormone, enobosarm and bimagrumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscle Wasting Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on muscle wasting disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for muscle wasting disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The muscle wasting disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medications; Physical Therapy; Nutritional Therapy; Surgery; Gene Therapy; Other Treatment Types
• 2) By Disorder Type: Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS); Other Disorder Types
• 3) By End-User: Hospitals; Rehab Centers; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Medications: Anabolic Steroids; Hormonal Treatments; Anti-Inflammatory Drugs; Immunomodulatory Agents
• 2) By Physical Therapy: Resistance Training; Stretching Exercises; Aerobic Conditioning; Rehabilitation Programs
• 3) By Nutritional Therapy: Protein Supplements; Nutritional Counseling; Dietary Modifications; Micronutrient Supplements
• 4) By Surgery: Surgical Interventions For Muscle Repair; Orthopedic Surgeries; Procedures For Underlying Conditions
• 5) By Gene Therapy: Gene Replacement Therapy; CRISPR-Based Approaches; RNA Interference Techniques
• 6) By Other Treatment Types: Complementary Therapies; Psychological Support; Assistive Devices
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Roche Holding AG; Novartis AG; Sanofi; GlaxoSmithKline (GSK); Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals; Acceleron Pharma Inc.; Biogen Inc.; Santhera Pharmaceuticals Holding AG; Mitsubishi Tanabe Pharma; Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.); Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; Ionis Pharmaceuticals Inc.; Axogen, Inc.; FibroGen Inc.; Cytokinetics Incorporated; Italfarmaco S.p.A.; Scholar Rock; Bellerophon Therapeutics; Akashi Therapeutics; aTyr Pharma; Metabolic Solutions Development Company; Synaptogenix; MyoKardia, Inc.; MyoTherix Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Muscle Wasting Disorders Market Characteristics

3. Muscle Wasting Disorders Market Trends And Strategies

4. Muscle Wasting Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Muscle Wasting Disorders Growth Analysis And Strategic Analysis Framework

• 5.1. Global Muscle Wasting Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Muscle Wasting Disorders Market Growth Rate Analysis
• 5.4. Global Muscle Wasting Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Muscle Wasting Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Muscle Wasting Disorders Total Addressable Market (TAM)

6. Muscle Wasting Disorders Market Segmentation

• 6.1. Global Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Physical Therapy
• Nutritional Therapy
• Surgery
• Gene Therapy
• Other Treatment Types
• 6.2. Global Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Muscular Dystrophy
• Amyotrophic Lateral Sclerosis (ALS)
• Other Disorder Types
• 6.3. Global Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Rehab Centers
• Specialty Clinics
• Other End-Users
• 6.4. Global Muscle Wasting Disorders Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anabolic Steroids
• Hormonal Treatments
• Anti-Inflammatory Drugs
• Immunomodulatory Agents
• 6.5. Global Muscle Wasting Disorders Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Resistance Training
• Stretching Exercises
• Aerobic Conditioning
• Rehabilitation Programs
• 6.6. Global Muscle Wasting Disorders Market, Sub-Segmentation Of Nutritional Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Supplements
• Nutritional Counseling
• Dietary Modifications
• Micronutrient Supplements
• 6.7. Global Muscle Wasting Disorders Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Interventions For Muscle Repair
• Orthopedic Surgeries
• Procedures For Underlying Conditions
• 6.8. Global Muscle Wasting Disorders Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Replacement Therapy
• CRISPR-Based Approaches
• RNA Interference Techniques
• 6.9. Global Muscle Wasting Disorders Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complementary Therapies
• Psychological Support
• Assistive Devices

7. Muscle Wasting Disorders Market Regional And Country Analysis

• 7.1. Global Muscle Wasting Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Muscle Wasting Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Muscle Wasting Disorders Market

• 8.1. Asia-Pacific Muscle Wasting Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Muscle Wasting Disorders Market

• 9.1. China Muscle Wasting Disorders Market Overview
• 9.2. China Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Muscle Wasting Disorders Market

• 10.1. India Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Muscle Wasting Disorders Market

• 11.1. Japan Muscle Wasting Disorders Market Overview
• 11.2. Japan Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Muscle Wasting Disorders Market

• 12.1. Australia Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Muscle Wasting Disorders Market

• 13.1. Indonesia Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Muscle Wasting Disorders Market

• 14.1. South Korea Muscle Wasting Disorders Market Overview
• 14.2. South Korea Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Muscle Wasting Disorders Market

• 15.1. Western Europe Muscle Wasting Disorders Market Overview
• 15.2. Western Europe Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Muscle Wasting Disorders Market

• 16.1. UK Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Muscle Wasting Disorders Market

• 17.1. Germany Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Muscle Wasting Disorders Market

• 18.1. France Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Muscle Wasting Disorders Market

• 19.1. Italy Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Muscle Wasting Disorders Market

• 20.1. Spain Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Muscle Wasting Disorders Market

• 21.1. Eastern Europe Muscle Wasting Disorders Market Overview
• 21.2. Eastern Europe Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Muscle Wasting Disorders Market

• 22.1. Russia Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Muscle Wasting Disorders Market

• 23.1. North America Muscle Wasting Disorders Market Overview
• 23.2. North America Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Muscle Wasting Disorders Market

• 24.1. USA Muscle Wasting Disorders Market Overview
• 24.2. USA Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Muscle Wasting Disorders Market

• 25.1. Canada Muscle Wasting Disorders Market Overview
• 25.2. Canada Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Muscle Wasting Disorders Market

• 26.1. South America Muscle Wasting Disorders Market Overview
• 26.2. South America Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Muscle Wasting Disorders Market

• 27.1. Brazil Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Muscle Wasting Disorders Market

• 28.1. Middle East Muscle Wasting Disorders Market Overview
• 28.2. Middle East Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Muscle Wasting Disorders Market

• 29.1. Africa Muscle Wasting Disorders Market Overview
• 29.2. Africa Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Muscle Wasting Disorders Market Competitive Landscape And Company Profiles

• 30.1. Muscle Wasting Disorders Market Competitive Landscape
• 30.2. Muscle Wasting Disorders Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi Overview, Products and Services, Strategy and Financial Analysis

31. Muscle Wasting Disorders Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline (GSK)
• 31.2. Eli Lilly and Company
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Regeneron Pharmaceuticals
• 31.5. Acceleron Pharma Inc.
• 31.6. Biogen Inc.
• 31.7. Santhera Pharmaceuticals Holding AG
• 31.8. Mitsubishi Tanabe Pharma
• 31.9. Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.)
• 31.10. Sarepta Therapeutics Inc.
• 31.11. PTC Therapeutics Inc.
• 31.12. Ionis Pharmaceuticals Inc.
• 31.13. Axogen, Inc.
• 31.14. FibroGen Inc.
• 31.15. Cytokinetics Incorporated

32. Global Muscle Wasting Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Muscle Wasting Disorders Market

34. Recent Developments In The Muscle Wasting Disorders Market

35. Muscle Wasting Disorders Market High Potential Countries, Segments and Strategies

• 35.1 Muscle Wasting Disorders Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Muscle Wasting Disorders Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Muscle Wasting Disorders Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer